Análisis genómico funcional de la resistencia a las terapias anti-EGFR asociada al fenotipo mesenquimal en el cáncer pulmonar.

2017

Lung cancer is the leading cause of cancer death in western countries. It is highly resistant to the conventional therapy, metastatic and with a 5-years survival rate of 15% for the most predominant histological subtype, non-small cell lung cancer (NSCLC). The improvements of genetic diagnosis, along with the latest advances in the design of chemicals inhibiting molecules targets (usually protein kinases), have provided a significant clinical benefit for a small subsets of patients whose tumors have activating mutations in genes encoding target proteins (called oncogenic drivers) critical for tumor progression such as ALK, MET, and EGFR in NSCLC. Specific inhibitors targeting tyrosine kinas…